<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03760588</url>
  </required_header>
  <id_info>
    <org_study_id>2017-004909-41</org_study_id>
    <nct_id>NCT03760588</nct_id>
  </id_info>
  <brief_title>Prevention of Cardiac Dysfunction During Breast Cancer Therapy</brief_title>
  <acronym>PRADAII</acronym>
  <official_title>PRevention of cArdiac Dysfunction During Adjuvant Breast Cancer Therapy: A Randomized, Placebo-controlled, Multicenter Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Torbjorn Omland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital, Akershus</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital of North Norway</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St. Olavs Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Helse Stavanger HF</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Klinbeforsk</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Norwegian Cancer Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Akershus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Breast cancer is the most common cancer among women. The modern post-surgery treatment with&#xD;
      chemotherapy, immunotherapy, radiation and hormone therapy has improved the overall 5-years&#xD;
      survival drastically. However, an unwanted effect of the post-surgery treatment is its&#xD;
      potentially deleterious effect on the heart resulting in cardiac dysfunction. Angiotensin&#xD;
      antagonists are used as part of the heart failure treatment. In smaller studies angiotensin&#xD;
      antagonists have shown to have a cardioprotective effect during breast cancer treatment.&#xD;
      Sacubitril/valsartan is a potent drug that in addition to an angiotensin antagonist contains&#xD;
      a neprilysin inhibitor. Sacubitril/valsartan has proved to be superior to enalapril in&#xD;
      chronic heart failure. In this randomized placebo controlled double blind trial we&#xD;
      hypothesize that sacubitril/valsartan used concomitantly during anthracycline containing&#xD;
      chemotherapy for breast cancer treatment prevents cardiac dysfunction as measured by cardiac&#xD;
      magnetic resonance imaging (CMR). PRADA II is a Norwegian multicenter trial intending to&#xD;
      recruit 214 patients and follow them for 18 months with CMR, cardiac ultrasound, blood&#xD;
      samples, functional capacity tests and health related quality of life questionnaires.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 14, 2019</start_date>
  <completion_date type="Anticipated">September 14, 2025</completion_date>
  <primary_completion_date type="Anticipated">September 14, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, placebo controlled, double blind design</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in left ventricular ejection fraction by cardiovascular magnetic resonance</measure>
    <time_frame>From randomization to end of blinded therapy (18 months)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in left ventricular ejection fraction by echocardiography</measure>
    <time_frame>From randomization to end of blinded therapy (18 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in left ventricular systolic global longitudinal strain by echocardiography</measure>
    <time_frame>From randomization to end of blinded therapy (18 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in left ventricular systolic global longitudinal strain by cardiovascular magnetic resonance (CMR)</measure>
    <time_frame>From randomization to end of blinded therapy (18 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in left ventricular end-systolic volume measured by CMR</measure>
    <time_frame>From randomization to end of blinded therapy (18 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of a significant reduction in left ventricular systolic function measured by CMR or echocardiography</measure>
    <time_frame>From randomization to end of blinded therapy (18 months)</time_frame>
    <description>An absolute reduction in LVEF ≥ 5% by CMR or a relative percentage reduction of global longitudinal strain (GLS) &gt; 15%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of cardiotoxicity measured by CMR or echocardiography</measure>
    <time_frame>From randomization to end of blinded therapy (18 months)</time_frame>
    <description>Absolute reduction in LVEF ≥ 10% to a value below 50% as measured either by CMR or Echocardiography, or incidence of clinical heart failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in circulating cardiac biomarkers</measure>
    <time_frame>From randomization to end of blinded therapy (18 months)</time_frame>
    <description>Cardiac biomarkers defined as cardiac troponins I and T measured by high sensitivity assays (hs-TnI and hs-TnT) and N-terminal proB-type natriuretic peptide (NT-proBNP)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Incidence of adverse events and serious adverse events</measure>
    <time_frame>From randomization to end of blinded therapy (18 months)</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">214</enrollment>
  <condition>Breast Cancer Female</condition>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Sacubitril/valsartan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sacubitril/valsartan (target dose 97/103 mg b.i.d.) and matching placebo will be provided orally in a 1:1 parallel fashion stratified by study site and for planned treatment with trastuzumab. Dose titration will be performed as follows: Sacubitril/valsartan 24/26 mg b.i.d. will be administered for 2-4 weeks and provided blood pressure &gt; 100 mmHg, no symptoms of hypotension or other side effects or adverse events (AE), followed by sacubitril/valsartan 49/51 mg b.i.d. for 2-4 weeks. Provided blood pressure &gt; 100 mmHg, no symptoms of hypotension or other side effects or AE a further uptitration to sacubitril/valsartan 97/103 mg b.i.d. will be performed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matched to the comparator.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sacubitril/valsartan</intervention_name>
    <description>Target dose 97/103 mg b.i.d .</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Sacubitril/valsartan</arm_group_label>
    <other_name>Entresto®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women with histological evidence of invasive early breast cancer scheduled for&#xD;
             adjuvant therapy with anti-cancer regimens that include anthracyclines&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group performance status 0-1&#xD;
&#xD;
          -  Sinus rhythm&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Age &lt;18 years&#xD;
&#xD;
          -  Renal failure, i.e. serum creatinine greater than 133 mol/L (1.5mg/dL) or estimated&#xD;
             glomerular filtration rate (eGFR) &lt; 45 mL/min/1.73m2&#xD;
&#xD;
          -  Hyperkalemia, i.e. serum potassium greater than 5.0 mmol/L&#xD;
&#xD;
          -  Systolic blood pressure &lt; 100 mgHg&#xD;
&#xD;
          -  Uncontrolled hypertension&#xD;
&#xD;
          -  Acute myocardial infarction within the last three months&#xD;
&#xD;
          -  Contraindication to ACEI or ARB or sacubitril/valsartan, including previous&#xD;
             hypersensitivity reaction, angioedema and renal artery stenosis&#xD;
&#xD;
          -  ACEI, ARB, aldosterone antagonist or sacubitril/valsartan use within 4 weeks of study&#xD;
             start&#xD;
&#xD;
          -  Clear indication for ACEI, ARB, aldosterone antagonist or sacubitril/valsartan&#xD;
             therapy, including symptomatic heart failure&#xD;
&#xD;
          -  History of hemodynamically significant valvular disease&#xD;
&#xD;
          -  Active liver disease, i.e. alanine aminotransferase or aspartate aminotransferase&#xD;
             greater than 1.5 times the upper limit of normal&#xD;
&#xD;
          -  Participation in another pharmaceutical clinical trial of an investigational medicinal&#xD;
             product (IMP) less than 4 weeks prior to inclusion or use of other investigational&#xD;
             drugs within 5 halflives of enrollment, whichever is longer&#xD;
&#xD;
          -  Conditions that would affect the participants to comply with the study protocol as&#xD;
             psychiatric or mental disorders, alcohol abuse or other substance abuse, suspected&#xD;
             poor drug compliance, language barriers or other factors&#xD;
&#xD;
          -  Contraindication or inability to undergo CMR examination&#xD;
&#xD;
          -  Fertile women with inadequate birth control, pregnancy, and/or breastfeeding. Adequate&#xD;
             contraception includes oral, injected or implanted hormonal methods of contraception,&#xD;
             placement of an intrauterine device or system, vasectomized partner or sexual&#xD;
             abstinence. Fertile women are defined as following menarche and until becoming&#xD;
             postmenopausal unless permanently sterile. A postmenopausal state is defined as no&#xD;
             menses for 12 months without an alternative medical cause&#xD;
&#xD;
          -  Life expectancy &lt; 12 months&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Torbjørn Omland, MD,PhD,MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Akershus</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Torbjorn Omland, MD,PhD,MPH</last_name>
    <phone>004740107050</phone>
    <email>torbjorn.omland@medisin.uio.no</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Geeta Gulati, MD,PhD</last_name>
    <phone>004799008982</phone>
    <email>geetagul@medisin.uio.no</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Akershus University Hospital</name>
      <address>
        <city>Lørenskog</city>
        <zip>1478</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jürgen Geisler, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stavanger University Hospital</name>
      <address>
        <city>Stavanger</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alf Inge Larsen, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of North Norway</name>
      <address>
        <city>Tromsø</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Egil Blix, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St Olavs Hospital</name>
      <address>
        <city>Trondheim</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Torgeir Wethal, MD, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>November 12, 2018</study_first_submitted>
  <study_first_submitted_qc>November 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 30, 2018</study_first_posted>
  <last_update_submitted>August 4, 2021</last_update_submitted>
  <last_update_submitted_qc>August 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Akershus</investigator_affiliation>
    <investigator_full_name>Torbjorn Omland</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>LCZ696</keyword>
  <keyword>CMR</keyword>
  <keyword>Echocardiography</keyword>
  <keyword>Cardio-oncology</keyword>
  <keyword>Circulating biomarkers</keyword>
  <keyword>Breast Cancer</keyword>
  <keyword>Anthracyclines</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valsartan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

